Last reviewed · How we verify
Apleway (TOFOGLIFLOZIN)
At a glance
| Generic name | TOFOGLIFLOZIN |
|---|---|
| Target | Sodium/glucose cotransporter 2 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 2014 |
Approved indications
- Diabetes mellitus type 2
Common side effects
Key clinical trials
- Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD) (PHASE2)
- SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD (PHASE4)
- Tofogliflozin GLP-1 Analogue Combination Trial (PHASE4)
- TOFO Insulin Combination Trial (PHASE4)
- Meta-analysis in Post-marketing Surveillances for SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus
- Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Apleway CI brief — competitive landscape report
- Apleway updates RSS · CI watch RSS